Revance Therapeutics, Inc., a biotechnology company searching for new innovations in neuromodulators for aesthetic and therapeutic indications, has announced the signing of a U.S. distribution agreement with Teoxane SA, making Revance the exclusive commercialization partner of the Swiss company’s Resilient Hyaluronic Acid (RHA) technology.
Read more from Revance >>